Trial Profile
A Phase III Randomized Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172/MK-8742 in Treatment-Naive Subjects With Chronic HCV GT1, GT4, GT5, and GT6 Infection Who Are on Opiate Substitution Therapy
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 21 Jun 2019
Price :
$35
*
At a glance
- Drugs Elbasvir/grazoprevir (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms C-EDGE CO-STAR
- Sponsors Merck Sharp & Dohme
- 19 Feb 2019 Results of integrated analysis of data from 12 international phase 2/3 clinical trials(NCT01717326,NCT01932762,NCT02092350,NCT02105467,NCT02105662,NCT02105688,NCT02105701,NCT02115321,NCT02203149,NCT02251990,NCT02252016 and NCT02358044) assessing safety and efficacy of Elbasvir/Grazoprevir in Asian Participants with Hepatitis C Virus Genotypes 1 and 4 Infection published in the Journal of Gastroenterology and Hepatology
- 13 Dec 2018 Status changed from active, no longer recruiting to completed.
- 13 Nov 2018 Results from Co-star par B of the study,presented at The Liver Meeting 2018: 69th Annual Meeting of the American Association for the Study of Liver Diseases